COVID-19: Read the latest research news and education updates

Einstein Community: Review policies & guidelines, access self-check app, and view dashboard.

  • Library
  • Intranet
Albert Einstein College of Medicine
  • About
  • Education
  • Research
  • Departments & Centers
Giving
Search
Menu
Montefiore Health System
  • Faculty Directory
  • Research Connections
  • Faculty Directory
  • Research Connections
Information For
  • Alumni
  • Donors
  • Faculty
  • Postdocs
  • Students (Prospective, Current)
  • Visitors
Quick Links
  • About
  • Administration
  • Departments & Centers
  • Directory
  • Education & Admissions
  • Events
  • Find Faculty
  • Giving
  • Health
  • Intranet
  • Library
  • Research
  • Webmail
News & Media
  • Newsroom
  • Blog
  • Einstein in the News
  • Expert List for Media
  • Features
  • Magazine
  • Multimedia
  • News Releases
  • Research Briefs
  • Social Media Hub

Faculty Profile

  • Home
  • Faculty Directory
  • Xingxing Zang, Ph.D.

Xingxing Zang, Ph.D.

Xingxing Zang

Professor, Department of Microbiology & Immunology

Professor, Department of Medicine (Oncology)

Professor, Department of Urology

Louis Goldstein Swan Chair in Women's Cancer Research

Area of Research: New T cell immune checkpoints; Cancer immunotherapy; Autoimmune diseases and immunotherapy; Metabolic diseases and immunotherapy; Infection and vaccines

Contact Information

718.430.4155718.430.8711

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus

1300 Morris Park Avenue
Forchheimer Building, Room 405A
Bronx, NY 10461

Research Profiles

More Resources: The Zang Immune Checkpoint and Immunotherapy Lab

Is this your profile? Edit profile

Professional Interests

T lymphocytes play a central role in the initiation and regulation of the adaptive immune response to antigen, whether foreign or native. The outcome of T cell engagement of antigen is determined by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 ligand family and their receptor CD28 family. We have recently discovered new members of the T cell costimulatory/coinhibitory B7 family and CD28 family including B7x, HHLA2 and TMIGD2, and have contributed to other immune checkpoints ICOS, PD-L1/PD-1, B7-H3, Tim-3, BTNL2, etc. We are using a variety of experimental approaches (gene knock-out mice, transgenic mice, monoclonal antibodies,crystal structure, patients samples, etc) to understand how new immune checkpoints regulate T cell activation and tolerance. Current emphasis in the lab is placed in the following areas: 1) Novel drugs development: Translational medicine of new immune checkpoints; 2) In vivo functions of new immune checkpoint pathways; 3) Human cancer-associated new B7/CD28 pathways and cancer immunotherapy; 4) Roles of new immune checkpoint pathways in autoimmune diseases/metabolic diseases and immunotherapy; 5) Relationship between new B7/CD28 pathways and infection; 6) Functional and structural characterization of new members of the immunoglobulin superfamily.

Our goal is to elucidate the mechanisms by which new immune checkpoints regulate T cells in peripheral non-lymphoid organs, and to translate the lessons learned in these studies towards developing new therapeutic strategies for cancers, autoimmune disorders, metabolic diseases, infectious diseases, and transplantation rejection.

Our research has formed scientific foundation and core intellectual property for several start-up drug companies. A novel immune checkpoint inhibitor derived from our lab is currently in clinical trials to treat cancer patients who have failed standard treatments or lack effective treatments. 

Since 2008 the lab has mentored total 45 trainees of MD-PhD or PhD students, postdoctoral fellows, clinical fellows, and visiting scientists. Many of trainees have subsequently moved on to independent careers in academic universities, medical centers, biopharmaceutical industry, and US government agencies.

 

Related News

  • Freeing Immune Cells to Combat Cancer
    Feature
    Freeing Immune Cells to Combat Cancer

    Mar 03, 2021

  • From Biomed to Basketball: M.D./Ph.D. Candidate Makes His Mark on Cancer Research and Bronx Kids' Program
    Feature
    From Biomed to Basketball: M.D./Ph.D. Candidate Makes His Mark on Cancer Research and Bronx Kids' Program

    May 08, 2019

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Bronx, NY 10461
718.430.2000
Affiliated With
Montefiore Health
Yeshiva University
  • About Einstein
    • History
    • Dean's Page
    Administration
    • Administrative Departments
    Alumni
  • Careers
    Centers (Research)
    Contact Us
    Departments
    Donors
    • Giving to Einstein
  • Education
    • Graduate Medical Education (G.M.E.)
    • Graduate Program (Ph.D.)
    • Master of Science in Bioethics (M.B.E.)
    • Master of Science in Clinical Research Methods (M.S.)
    • Medical Program (M.D.)
    • MSTP Program (M.D. - Ph.D.)
  • Einstein Senate
    Faculty Directory
    Health
    • Affiliated Institutions
    • Clinical Programs
    • Global Health
    • E-M Partnership
    INTRANET
    Library
    Luminis Portal
  • Newsroom
    • Blog
    • Einstein in the News
    • Expert List for Media
    • Features
    • Magazine
    • Multimedia
    • News Releases
    • Research Briefs
    • Social Media Hub
  • Policies
    Research
    • Collaboration Zone
    • Scientific Resources
    Video
    Visitors
    • Campus Map
    • Directions
    Webmail
ALBERT EINSTEIN ®
College of Medicine
© Albert Einstein College of Medicine | Privacy Policy | Terms of Use | Webmaster
Click here to log in